Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EC-MPS | Drug |
Inclusion Criteria:
Patients who were participating in the core study CERL080A2401 and have successfully completed the first 12 months of the core study
Exclusion Criteria:
Patients who did not complete the 12-month core study CERL080A2401
Other protocol-defined inclusion/exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis | Novartis | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided